Amanda Parkes

2.1k total citations
36 papers, 391 citations indexed

About

Amanda Parkes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Amanda Parkes has authored 36 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Amanda Parkes's work include Childhood Cancer Survivors' Quality of Life (8 papers), Sarcoma Diagnosis and Treatment (6 papers) and Lung Cancer Research Studies (5 papers). Amanda Parkes is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (8 papers), Sarcoma Diagnosis and Treatment (6 papers) and Lung Cancer Research Studies (5 papers). Amanda Parkes collaborates with scholars based in United States, Spain and Netherlands. Amanda Parkes's co-authors include Zhubin Gahvari, Jennifer K. Litton, Roberto Carmagnani Pestana, Oluchi Oke, Katherine Clifton, Gabriel N. Hortobágyi, Carla L. Warneke, Helen Knight, Areej El‐Jawahri and Jennifer S. Temel and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Amanda Parkes

31 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amanda Parkes United States 12 222 132 65 56 56 36 391
J.M. Jonker Netherlands 6 187 0.8× 121 0.9× 102 1.6× 35 0.6× 86 1.5× 6 609
Wee Kheng Soo Australia 12 189 0.9× 102 0.8× 95 1.5× 33 0.6× 40 0.7× 23 600
Diana Almader‐Douglas United States 11 175 0.8× 88 0.7× 61 0.9× 70 1.3× 65 1.2× 30 442
Ersin Özaslan Türkiye 13 276 1.2× 127 1.0× 59 0.9× 30 0.5× 56 1.0× 40 416
Birsen Yücel Türkiye 11 205 0.9× 123 0.9× 28 0.4× 37 0.7× 64 1.1× 53 362
Luciano Paladini Brazil 8 213 1.0× 96 0.7× 46 0.7× 28 0.5× 97 1.7× 20 526
Elisabeth Diver United States 16 271 1.2× 102 0.8× 58 0.9× 47 0.8× 181 3.2× 57 775
J.P. Jacquin France 8 215 1.0× 106 0.8× 27 0.4× 19 0.3× 79 1.4× 12 512
Nalliah Manoharan India 12 118 0.5× 108 0.8× 33 0.5× 36 0.6× 76 1.4× 21 338
Neyran Kertmen Türkiye 11 333 1.5× 100 0.8× 90 1.4× 47 0.8× 22 0.4× 56 491

Countries citing papers authored by Amanda Parkes

Since Specialization
Citations

This map shows the geographic impact of Amanda Parkes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Parkes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Parkes more than expected).

Fields of papers citing papers by Amanda Parkes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda Parkes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Parkes. The network helps show where Amanda Parkes may publish in the future.

Co-authorship network of co-authors of Amanda Parkes

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda Parkes. A scholar is included among the top collaborators of Amanda Parkes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda Parkes. Amanda Parkes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Chiang, Anne C., Noemı́ Reguart, Philipp J. Jost, et al.. (2024). 155P Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1. Immuno-Oncology Technology. 24. 100784–100784. 1 indexed citations
4.
Dowlati, Afshin, Horst-Dieter Hummel, Stéphane Champiat, et al.. (2024). Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. Journal of Clinical Oncology. 42(29). 3392–3399. 22 indexed citations
5.
Champiat, Stéphane, Michael Boyer, Kai He, et al.. (2024). 195MO Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity. ESMO Open. 9. 102768–102768. 2 indexed citations
6.
Montgomery, Kathleen, et al.. (2023). A Midwest Stakeholder Evaluation of an Adolescent and Young Adult Cancer Survivor Needs Assessment Survey. Journal of Adolescent and Young Adult Oncology. 13(1). 123–131.
7.
Osman, Fauzia, et al.. (2023). Benefit of Interdisciplinary Care in Resource Identification in an Adolescent and Young Adult Oncology Care Model. Journal of Adolescent and Young Adult Oncology. 12(5). 752–757. 1 indexed citations
8.
Osman, Fauzia, et al.. (2022). Disparities in Treatment Satisfaction and Supportive Care Receipt for Young Adult Oncology Patients on the Basis of Residential Location. JCO Oncology Practice. 18(9). e1542–e1552. 1 indexed citations
9.
Livingston, J. Andrew, Yeonhee Park, Keith M. Skubitz, et al.. (2022). Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. Cancer Medicine. 11(18). 3471–3478. 7 indexed citations
10.
Pestana, Roberto Carmagnani, et al.. (2021). Impact of tissue-agnostic approvals for patients with sarcoma. Trends in cancer. 8(2). 135–144. 12 indexed citations
11.
Parkes, Amanda, et al.. (2021). Impact of psychosocial factors on the receipt of guideline concordant care in adolescent and young adults with localized Ewing sarcoma and osteosarcoma.. Journal of Clinical Oncology. 39(15_suppl). e18658–e18658. 1 indexed citations
12.
Osman, Fauzia, et al.. (2021). Disparities Between Provider Assessment and Documentation of Care Needs in the Care of Adolescent and Young Adult Patients With Sarcoma. JCO Oncology Practice. 17(6). e891–e900. 8 indexed citations
13.
Pestana, Roberto Carmagnani, et al.. (2021). Systemic Options for Malignant Peripheral Nerve Sheath Tumors. Current Treatment Options in Oncology. 22(4). 33–33. 19 indexed citations
14.
Parkes, Amanda, Wei‐Lien Wang, Shreyaskumar Patel, et al.. (2021). Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Research and Treatment. 186(3). 871–882. 15 indexed citations
15.
LoConte, Noelle K., et al.. (2020). Variation in Breast Cancer Screening Recommendations by Primary Care Providers Surveyed in Wisconsin. Journal of General Internal Medicine. 35(9). 2553–2559. 6 indexed citations
16.
Parkes, Amanda, Priya Bhosale, Heather Lin, et al.. (2020). PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma. 2020. 1–6. 18 indexed citations
17.
Hirbe, Angela C., Jingqin Luo, ­Mahesh Seetharam, et al.. (2020). A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. European Journal of Cancer. 137. 1–9. 12 indexed citations
18.
Hirbe, Angela C., Jingqin Luo, ­Mahesh Seetharam, et al.. (2019). A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy. Annals of Oncology. 30. v688–v688.
19.
Parkes, Amanda, Katherine Clifton, Oluchi Oke, et al.. (2018). Characterization of bone only metastasis patients with respect to tumor subtypes. npj Breast Cancer. 4(1). 2–2. 44 indexed citations
20.
Scott, David A., Amanda Parkes, Frédérique Ponchel, et al.. (2007). Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. International Journal of Oncology. 31(3). 557–65. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.M. Jonker Breakdown of academic impact, for papers by Wee Kheng Soo Breakdown of academic impact, for papers by Diana Almader‐Douglas Breakdown of academic impact, for papers by Ersin Özaslan Breakdown of academic impact, for papers by Birsen Yücel Breakdown of academic impact, for papers by Luciano Paladini Breakdown of academic impact, for papers by Elisabeth Diver Breakdown of academic impact, for papers by J.P. Jacquin Breakdown of academic impact, for papers by Nalliah Manoharan Breakdown of academic impact, for papers by Neyran Kertmen
Rankless by CCL
2026